Reclassification of 14 Peptides Sends Hims & Hers Stock Up 7.6% to $15.79
U.S. Health Secretary reclassified 14 peptide compounds from FDA Category 2 to Category 1, enabling compounding pharmacies like Hims & Hers’ newly acquired California facility to legally produce them. Shares surged 7.58%, with RSI at 15.87 despite a 61.75% annual decline.
1. Regulatory Recategorization of Peptide Compounds
U.S. Health Secretary Robert F. Kennedy Jr. announced that 14 peptide compounds will be reclassified from FDA Category 2 to Category 1, removing compounding prohibitions and allowing U.S. pharmacies to legally produce these treatments.
2. Hims & Hers Operational Readiness
Hims & Hers acquired a California peptide compounding facility in 2025 and is positioned to capture demand from consumers currently sourcing peptides through grey-market channels, bolstering its personalized wellness product lineup.
3. Stock Performance and Technical Indicators
Shares jumped 7.58% and traded between $14.31 and $15.79 on the day, even as the stock sits 17.1% below its 20-day and 64.7% below its 200-day moving averages; the RSI at 15.87 and a bullish MACD crossover suggest potential stabilization.